Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Operations (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Cash from Operations data on record, last reported at 100428000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations rose 578.37% year-over-year to 100428000.0; the TTM value through Sep 2025 reached 149138000.0, up 360.31%, while the annual FY2024 figure was 41996000.0, 195.88% up from the prior year.
  • Cash from Operations reached 100428000.0 in Q3 2025 per GLUE's latest filing, up from 34720000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 128922000.0 in Q4 2024 and bottomed at 45492000.0 in Q1 2025.
  • Average Cash from Operations over 3 years is 1673636.36, with a median of 24706000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: crashed 63.06% in 2024, then skyrocketed 578.37% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 29634000.0 in 2023, then skyrocketed by 335.05% to 128922000.0 in 2024, then dropped by 22.1% to 100428000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 100428000.0 in Q3 2025, 34720000.0 in Q2 2025, and 45492000.0 in Q1 2025.